1. Introduction {#sec1}
===============

Understanding the models established by human induced pluripotent stem cells (hiPSCs) requires genome-wide mapping to elucidate gene regulatory networks \[[@B1], [@B2]\]. Therefore, transcriptome analysis has been used to compare hiPSC-derived lineage-specific cells with somatic counterparts \[[@B3]\]. Recently, forebrain spheroids or organoids were derived from hiPSCs for disease modeling and as potential platforms for drug screening \[[@B4]--[@B7]\]. These spheroids need to contain critical components of the human brain, such as vascular cells and microglia, for proper function. Our previous study characterized microglia-like cells differentiated from hiPSCs and introduced isogenic microglia-like cells into forebrain spheroids \[[@B8]\]. The microglia-like cells were cocultured with isogenic dorsal cortical spheroids in order to build immune function within the spheroids. While extensive phenotypic characterizations were performed in our previous study, the fundamental metabolic pathways and signaling pathways in different culture systems were not analyzed yet. It is postulated that the microglia-like cells inside the spheroids retain more *in vivo*-like metabolic program and the associated phenotype due to the environmental change in intimate cell-cell and cell-matrix interactions compared to 2-D culture.

Metabolic programming was found to play important roles in homeostasis, tissue repair, immune function, epigenetic change, and cellular phenotype. For hiPSC reprogramming, the somatic cells with oxidative phosphorylation (OXPHOS) gain the glycolysis metabolism when they gain pluripotency \[[@B9], [@B10]\]. For human mesenchymal stem cell (MSC) aggregates, metabolic reconfiguration towards glycolysis supports reacquisition of the primitive stem cell phenotype \[[@B11]\]. Similarly, for microglia, limited data suggest that polarization to an M1 phenotype (proinflammatory) may be accompanied by a metabolic shift from oxidative phosphorylation to aerobic glycolysis for energy production \[[@B12], [@B13]\]. It has been suggested that default polarization of resident microglia uses OXPHOS (mitochondrial respiration, i.e., anti-inflammatory M2 phenotype) for the functions involved in tissue repair, while the metabolic program shifts towards glycolysis as well as nitric oxide and citrulline production for M1 polarization \[[@B12]\]. In addition, the metabolic environment of microglia can affect brain region-dependent gene regulation \[[@B13]\]. Therefore, modifications of immune response by the physiological 3-D microenvironment may reshape the innate immunity that gains the "memory" and "trained" inflammation response \[[@B12]\].

Based on the literature for metabolic programming of 3-D HepG2/C3A spheroids \[[@B14]\], this present study analyzed the genomics data for hiPSC-derived microglia-like cells (i.e., single cells in semiadherent culture) and the isogenic 3-D dorsal spheroids containing microglia-like cells. The focus is on changes in metabolic pathways and the signaling pathways that are involved in cell proliferation, cell death, inflammation, PIK3/AKT/mTOR signaling, and Wnt and Notch pathways in 3-D cortical spheroids derived from hiPSCs. This study provides global genomic details on the impact of 3-D culturing on the metabolic phenotype of cells inside the cortical spheroids. The analysis in this study can also help to establish better coculturing strategies for mimicking the *in vivo* structure and functions of the central nervous system *in vitro*.

2. Materials and Methods {#sec2}
========================

2.1. Microglia-Like Cells Derived from iPSCs {#sec2.1}
--------------------------------------------

Our lab has derived microglia-like cells from human iPSK3 cells free of feeders using a modified protocol \[[@B15]\]. Mesoderm induction was performed using activin A, BMP4, SCF, and VEGF, followed by SCF, Flt3L, IL-3, and GM-CSF treatment. Nonadherent cells were replated to tissue culture-treated plates in the presence of IL-3 and M-CSF. The day 23 cells expressed 48-59% CD11b and 52-64% CD45. Day 28 cells expressed 70 ± 6% CD11b and 80 ± 5% IBA-1. Day 30-33 cells expressed 68 ± 12% P2RY12 and 51 ± 10% CX3CR1 ([Figure 1(a)](#fig1){ref-type="fig"}) \[[@B8]\].

2.2. Generation of Isogenic Dorsal Cortical Spheroids and Coculturing with Microglia-Like Cells {#sec2.2}
-----------------------------------------------------------------------------------------------

Neural differentiation was induced using dual SMAD inhibitors LDN193189 (LDN) and SB431542 (SB) on human iPSK3 cells in low attachment 96-well plates. The neural progenitor spheres were treated with patterning factors cyclopamine (a sonic hedgehog inhibitor) and fibroblast growth factor- (FGF-) 2 \[[@B7], [@B16]\]. The dorsal identity is defined by TBR1, PAX6, BRN2, and SATB2.

Dorsal spheroids (day 30) were cocultured with isogenic microglia-like cells at a 4 : 1 ratio (8 × 10^5^ neurons to 2 × 10^5^ microglia-like cells, i.e., 20%) in 50% DMEM/10% FBS and 50% neural differentiation medium composed of DMEM/F12 plus 2% B27 (Figures [1(b)](#fig1){ref-type="fig"} and [1(c)](#fig1){ref-type="fig"}). The CellTracker Red-labeled MGs were observed to move into the D-MG spheroids ([Figure 1(c)](#fig1){ref-type="fig"}). After three days of coculture (day 33), the dorsal spheroids containing microglia-like cells (D-MG group) and the microglia cells only (MG group) were harvested for RNA isolation and RNA-sequencing.

2.3. RNA-Sequencing {#sec2.3}
-------------------

mRNA was isolated from the total RNA using the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs). cDNA libraries were generated from the isolated mRNA using an NEBNext Ultra RNA Library Prep Kit for Illumina (New England Biolabs), with a unique 6-nucleotide index primer (NEBNext Multiplex Oligos for Illumina), using Beckman Biomek 4000. The multiplexed sample was quantified with qPCR (Kapa Biosystems) specific for Illumina sequencing primers, and the average fragment size was determined with a Bioanalyzer High-Sensitivity DNA Chip (Agilent Technologies). The sequencing was performed on Illumina HiSeq 2500 at the Translational Science Laboratory of Florida State University. The pooled data were demultiplexed into individual sample data, and adapter primer sequences were removed \[[@B17]\].

2.4. RNA-Sequencing Data Analysis {#sec2.4}
---------------------------------

The sequencing reads were analyzed using RNA-Seq Alignment version 1.1.1 (Illumina BaseSpace application). The reads were aligned with TopHat 2 \[[@B18]\] to the human genome (genome release GRCh38) using default parameters, and counts for each gene were generated. This workflow uses Cufflinks to generate FPKM (fragments per kilobase per million reads) normalized values \[[@B19]\]. DESeq2 was used to determine statistically significant differentially expressed genes (a false discovery rate (FDR) of \<0.05 was used). 15,585 genes were considered to be expressed in this study by the DESeq2 software \[[@B20]\]. The top 500 genes that were upregulated and downregulated (1000 total genes) in the microglial culture versus the D-MG group were assessed for GO, KEGG pathway, and phenotype pathway analysis using WebGestalt \[[@B21], [@B22]\]. Significant enrichment was determined in WebGestalt using the hypergeometric test and the Benjamini-Hochberg FDR method \[[@B23]\] for multiple testing adjustment.

2.5. Reverse Transcription Polymerase Chain Reaction (RT-PCR) Analysis {#sec2.5}
----------------------------------------------------------------------

Total RNA was isolated from different cell samples using the RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer\'s protocol followed by the treatment with a DNA-Free RNA Kit (Zymo, Irvine, CA) \[[@B24]\]. Reverse transcription was carried out using 2 g of total RNA, anchored oligo-dT primers (Operon, Huntsville, AL), and Superscript III (Invitrogen, Carlsbad, CA) (according to the protocol of the manufacturer). Primers specific for target genes (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}) were designed using the software Oligo Explorer 1.2 (GeneLink, Hawthorne, NY). The gene *β*-actin was used as an endogenous control for normalization of expression levels. Real-time RT-PCR reactions were performed on an ABI7500 instrument (Applied Biosystems, Foster City, CA), using SYBR1 Green PCR Master Mix (Applied Biosystems). The amplification reactions were performed as follows: 2 min at 50°C, 10 min at 95°C, and 40 cycles of 95°C for 15 sec and 55°C for 30 sec and 68°C for 30 sec. Fold variation in gene expression was quantified by means of the comparative Ct method: 2^−(Δ*C*~*t* treatment~\ −\ Δ*C*~*t* control~)^, which is based on the comparison of expression of the target gene (normalized to the endogenous control *β*-actin) between the compared samples.

3. Results and Discussions {#sec3}
==========================

Previously, our study derived and characterized microglia-like cells from the healthy iPSK3 cells and Ep-iPSC cells \[[@B8]\]. The cells were cocultured and integrated with isogenic dorsal cortical spheroids (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}). The whole-cell transcriptome analysis was performed for the microglial phenotype, neural inflammation, and the genes involved in Alzheimer\'s disease. Our current study focuses on different attributes of the 3-D dorsal cortical spheroids containing isogenic microglia-like cells (D-MG group) vs. microglia-like cells (MG group), including metabolic pathways and the signaling pathways that are involved in cell proliferation, cell death, inflammation, PIK3/AKT/mTOR signaling, EIF2 pathway, and Wnt and Notch pathways, which were not reported previously.

3.1. Central Metabolic Pathway {#sec3.1}
------------------------------

The 3-D spheroid culture usually is associated with slow growth rates, cytoskeleton reorganization, enhanced tight junctions and polarity, and the relocated membrane transporters \[[@B25]--[@B27]\]. In aerobic glycolysis, glucose is consumed through the glycolytic pathway to produce lactic acid, nucleotides, amino acids, and other metabolites, while glutamine is converted through glutaminolysis to citrate for cholesterol and lipid production. In oxidative phosphorylation, the generated pyruvate is oxidized to CO~2~ and water through the tricarboxylic (TCA) cycle, which produces ATP and coverts NADH to NADPH \[[@B28]--[@B30]\].

The central metabolic pathways are shown in [Figure 2](#fig2){ref-type="fig"}. The values were calculated using log2 (DMG/MG). Relative enzyme expression levels indicate an increase in glycolytic and pentose phosphate pathways in the D-MG group as well as the increased amino acid synthesis ([Figure 2](#fig2){ref-type="fig"} and Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}) \[[@B31]\]. The increased glycolysis is permissive to trigger microbiocidal activity of microglia and allows the cells to survive in the 3-D spheroids. However, enzymes in the glutaminolytic pathway, hexosamine, nucleotide, lipid synthesis, and TCA cycle have small differences among the two groups. Genes related to ATP synthesis and mitochondrial complexes I, III, and IV are shown in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"} and Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}. The differences between the two groups are small (within ±0.5 except NDUFA13 at -0.68). But the values are all negative for genes related to ATP synthesis and mitochondrial complexes I and III, indicating lower expression in the D-MG group. Together, these results indicate the different energetic/metabolic phenotypes between the D-MG and the MG groups.

Metabolic shift towards glycolysis usually results in the elevated dependence on glutaminolysis or fatty acid synthesis in cell metabolism \[[@B32]\]. However, in this study, the cells did not show a significant increase in glutaminolysis in the spheroids ([Figure 2](#fig2){ref-type="fig"} and Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}). Cytoplasmic isocitrate dehydrogenase 1 (IDH-1) is involved in the reaction of isocitrate production from *α*-ketoglutarate in the cytosol. IDH-1 expression is decreased in the D-MG spheroids, which may be associated with NF-*κ*B activation in a hypoxia-inducible factor- (HIF-1*α*-) dependent manner \[[@B33]\].

Similarly, 3-D culture of iPSC-derived endothelial cells also showed the glycolysis-dominated metabolism compared to ones in 2-D culture \[[@B34]\]. Moreover, human MSCs treated with interferon gamma exert an immunosuppressive phenotype by secreting PGE2/IDO and reconfigure the metabolic phenotype to aerobic glycolysis \[[@B35]\]. It was also suggested that activation of the AKT/mTOR signaling pathway is required for metabolic shift under this immune polarization.

The 3-D cultures may not always enhance the glycolysis, which is dependent on a specific cell type. For example, it was reported that 3-D cultures of hiPSC-derived cardiomyocytes displayed downregulation of genes involved in glycolysis and lipid biosynthesis and upregulation of genes involved in oxidative phosphorylation. Accordingly, the 3-D cultures showed lower fluxes for fatty acid synthesis and the increased TCA cycle activity, which improved both cell purity and metabolic maturation \[[@B36]\].

3.2. Hypoxia (Glycolysis and Oxidative Phosphorylation) {#sec3.2}
-------------------------------------------------------

### 3.2.1. HIF-1*α* Pathway {#sec3.2.1}

In 3-D spheroid culture, the inside of the spheroids is thought to be more hypoxic than the surface due to mass transfer limitation of oxygen \[[@B37]\], while this has been challenged by other studies as nonhypoxia-stabilized HIF expression \[[@B25]\]. Hypoxia is an important factor in regulating stem cell metabolism and phenotype \[[@B38]\]. When oxygen concentrations decrease, the oxygen-dependent prolyl hydroxylase domain proteins are inactivated and the HIF-1*α* protein is accumulated, which promotes HIF-1*α* translocation to the nucleus and its binding to hypoxia response elements, such as glucose transporters and glycolytic enzymes \[[@B39], [@B40]\]. Our results do not show the higher HIF-1*α* gene expression in the D-MG group but demonstrate the increased expression of HIF-1*α* pathway downstream genes, including SIAH2 (1.29), PDK1 (3.84), LDHA (1.99), LONP1 (1.94), and P4HA1 (1.79) (Figures [3(a)](#fig3){ref-type="fig"}--[3(c)](#fig3){ref-type="fig"}). These results may indicate the nonhypoxia-stabilized HIF expression in the D-MG group. The downregulated HIF-1*α* gene expression in the D-MG group was also validated using RT-PCR, along with the upregulated glycolytic gene expression in the D-MG group (Figures [3(d)](#fig3){ref-type="fig"} and [3(e)](#fig3){ref-type="fig"}).

HIF-1*α* induces pyruvate dehydrogenase kinase 1 (PDK1) expression, which inhibits mitochondrial pyruvate dehydrogenase (PDH) \[[@B38], [@B41]\]. This reduces pyruvate flux into the TCA cycle and lowers the mitochondrial oxygen requirements. The lactate production and secretion would be increased, as observed by Sart et al. \[[@B9]\]. HIF-1*α* also induces E3-ubiquitin ligase SIAH2 synthesis, which mediates the proteasomal degradation of the OGDH subunit of *α*-ketoglutarate dehydrogenase (*α*-KD) and forms a part of the feedback control of HIF-1*α* signaling. A modest reduction of the *α*-KD enzyme complex was observed in the D-MG group (DLD, -0.75, OGDH, -1.71) ([Table 1](#tab1){ref-type="table"}), which may slow down TCA cycle activity. Interestingly, the citrate transportation into the cytoplasm by citrate transporter protein (SLC25A1, -0.25) was relatively comparable between these two groups. The extracellular matrix remodeling via collagen hydroxylases (P4HA1, 1.79) was upregulated in the D-MG group. The amounts of anabolic rate-limiting enzymes were increased or remained similar, while catabolic enzymes were unchanged between the two groups ([Table 2](#tab2){ref-type="table"}). The rate-limiting glycolytic pathway steps (HK2, PKM, and PFKL) are the mostly increased enzymes of the pathway. These findings are consistent with the metabolic shift to aerobic glycolysis. In addition, high PFK level may also indicate high levels of AMP, since the spheroids usually have high ATP amounts \[[@B14]\].

HIF-1*α* signaling can induce the expression of the mitochondrial protease LONP1 (1.94) ([Figure 3](#fig3){ref-type="fig"}). LONP1 degrades cytochrome C oxidase 4 subunit 1 (COX4-1) through electron transport chain complex IV, allowing the replacement of COX4-1 by COX4-2 \[[@B42]\], which is more efficient in enzymatic reaction. LONP1 is an essential central regulator of mitochondrial activity and is overexpressed during oncogenesis \[[@B43]\]. Although LONP1 was increased (1.94) based on our results, there was little change in the level of COX4-1 (-0.12). Reduced mitochondrial respiration normally results in fewer reactive oxygen species (ROS), correlated with the reduced level of catalase (CAT, -1.55). The reduced oxidative stress results in the diminished hydrogen peroxide damage and less oxidized proteins \[[@B14]\].

### 3.2.2. Glutamine Metabolism and Hexosamine Pathway {#sec3.2.2}

While the D-MG group mainly uses glycolysis as its major energetic metabolism, our results did not show an increased reliance on glutamine metabolism ([Figure 2](#fig2){ref-type="fig"} and Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}). Intracellular glutamine levels are regulated by plasma membrane transporters SLC38A2 and SLC1A5 \[[@B14]\]. Endoplasmic reticulum stress would induce the degradation of transporters and ultimately autophagy and cell death \[[@B14]\]. In D-MG spheroids of this study, both SLC38A2 (-0.53) and SLC1A5 (-1.86) were decreased, which may suggest enhanced autophagy in D-MG spheroids.

*(1) Conversion of Glutamine into Glutamate*. The glutamate demand of the cells is indicated by the expression of GFPT1 (-0.66). GFPT1 is the first and rate-limiting step of the hexosamine pathway and catalyzes the conversion of fructose 6-phosphate and glutamine to glucosamine 6-phosphate and glutamate. Consistently in this study, several enzymes in polysaccharide, proteoglycan, and glycosylation synthetic pathways were downregulated in the D-MG spheroids, including UDP-glucose pyrophosphorylase UGP2 (-0.51), UDP-glucose 6-dehydrogenase UGDH (-1.18), and UDP-glucose 4-epimerase GALE (-1.31).

*(2) α-Ketoglutarate*. Glutamate can be converted to *α*-ketoglutarate by the mitochondrial GLUD1 (-0.33) or by cytoplasmic alanine or aspartate aminotransferases \[[@B44]\]. The cytoplasmic enzymes were slightly upregulated (GOT1, 0.36, GOT2, 0.69) in the D-MG group. There are three possible routes by which *α*-ketoglutarate can be converted to citrate ([Figure 2](#fig2){ref-type="fig"}) \[[@B1]\]. It can be converted through the TCA cycle \[[@B2]\]. It could be converted from isocitrate to citrate (by IDH2, -0.39, and ACO2, 0.01), which affects the normal TCA cycle flux by reductive glutamate metabolism \[[@B32]\]. In this study, IDH3B was slightly increased (0.36) and it can only catalyze the "forward" reaction \[[@B3]\]. Cytoplasmic *α*-ketoglutarate, produced through GFPT1 (-0.66) and GOT1 (0.36), can be converted by IDH1 (-1.01) and ACO1 (-0.73), which are both downregulated in the D-MG group compared to the MG group.

*(3) NADH*. NADH/NAD+ and NADPH/NADP+ conversions are critical in the central metabolic pathways ([Figure 2](#fig2){ref-type="fig"} and Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}). The reduction in the mitochondrial MDH1 (-0.49) and the downregulation of NAD(P) transhydrogenase (NNT, -1.24) suggest that the conversions in mitochondria may have some significance. MDH1 was decreased (-0.49) but lacked a malate source (e.g., the SLC25A11 transporter was essentially unchanged (0.25)). The conversion of cytoplasmic pyruvate to lactate would consume the produced NADH. The richest source of NADPH is the pentose phosphate pathway, where G6PD (-0.16) was essentially unchanged between the two groups. These results indicate the reliance on mitochondrial NAD+/NADH in the D-MG group.

*(3) Citrate*. Citrate can be used for fatty acid synthesis. ATP-citrate synthase uses citrate to generate cytosolic acetyl-CoA. Acetyl-CoA is used for (1) histone acetylation by acetyl-CoA acyltransferase (ACAA1, -0.28), (2) fatty acid synthesis (FASN, 0.34), and (3) synthesis of cholesterol, steroid hormones, and other biomolecules. Glutamine is as important as glucose in metabolism, and it can block glutamate-dependent cellular pathways at either IDH1 or ACL step \[[@B14]\].

3.3. Signaling Pathways Involved in Metabolic Reprogramming {#sec3.3}
-----------------------------------------------------------

The analysis so far shows the metabolic shift to aerobic glycolysis in the 3-D spheroids, which may be driven by diffusion gradients \[[@B30], [@B37]\]. In order to investigate how metabolic reprogramming is orchestrated, the status of critical pathways for cellular function, including PI3K/AKT/mTOR, Myc, p53, NF-*κ*B, EIF2, Wnt, and Notch, was analyzed.

### 3.3.1. PIK3/AKT/mTOR Signaling {#sec3.3.1}

PI3K (a class I phosphoinositide 3-kinase) is one of the key signaling enzymes that are activated in 3-D spheroid cultures \[[@B45]\]. And the PIK3 pathway is directly related to cellular metabolism and growth. When cells consume the nutrients and growth factors, they generate amino acids, glucose, oxygen, and energy (i.e., ATP) and use these products to activate GTPase, such as Rheb, through PI3K. One key regulator of metabolism and growth-activated downstream of PI3K signaling is the mechanistic target of rapamycin (mTOR) \[[@B46]\]. Our results showed that the expression of mTOR (0.66) was slightly elevated in the D-MG spheroids and the downstream effectors were inhibited (e.g., ribosomal protein s6 kinase RPS6KA3, -1.87) ([Figure 4(a)](#fig4){ref-type="fig"}). mTOR stimulates pyrimidine synthesis via the RPS6KA-mediated phosphorylation of CAD (0.46), whereas AKT can phosphorylate ACL, enhancing its lipogenic activities and mTOR signaling. The expression of ACLY (-0.13) indicates that the activity of the AKT pathway was similar in the two groups. mTOR regulates several anabolic and catabolic pathways through fatty acid and cholesterol biosynthetic genes via the SREBP family (SREBP1 and SREBP2) \[[@B47]\].

mTOR signaling was reported to increase the translation of HIF-1*α*, glucose transporters, and glycolytic enzymes and promote metabolic reprogramming. The activation of the mTOR protein complex mTORC1 leads to the induction of genes encoding the enzymes of glycolysis, the pentose phosphate pathway, and lipid and sterol biosynthesis \[[@B35], [@B48]\]. mTOR was also reported to coordinate the activation of cell growth machinery together with amino acids in the presence of growth signals \[[@B49]\]. However, in the RT-PCR validation, mTOR gene expression was statistically insignificant, possibly due to assay variations (Figures [4(b)](#fig4){ref-type="fig"} and [4(c)](#fig4){ref-type="fig"}). In addition, ERK1 was downregulated while ERK2 was upregulated in the D-MG group.

### 3.3.2. Myc Signaling {#sec3.3.2}

Myc is a transcription factor that dimerizes with MAX to bind to DNA and regulate gene expression involved in metabolism (glycolysis and glutaminolysis) and biosynthesis (nucleotide and lipid synthesis) \[[@B50]\]. Myc supports specific mRNA splice variants, such as glycolysis-affecting PKM2 over PKM1. Myc targets glucose membrane transporters such as GLUT1 (or SLC2A1) and glutamine transporter SLC1A5, which are important in cell proliferation \[[@B50]\]. Myc transactivates the gene expression of PFK, ENO, and LDHA (1.99) and indirectly increases GAPDH and PGK1, based on our genomics analysis (PGK1, 3.54; GPI, 5.07; ENO1, 3.30; and GAPDH, 2.02), indicating the relation between Myc and glycolysis ([Figure 5](#fig5){ref-type="fig"}). The gene expression of Myc-related proteins was downregulated in the D-MG spheroids including PTBP1 (-0.60), SLC1A5 (-1.86), and PRDX3 (-1.77) ([Figure 5](#fig5){ref-type="fig"}). The low Myc activity inside the D-MG spheroids might indicate the slow proliferation of cells.

### 3.3.3. p53 Signaling {#sec3.3.3}

In addition, the expression of the transcriptional suppressor CDK5RAP3 is comparable between the D-MG group and the MG group (0.34). CDK5RAP3 is a novel activator of PAK4 and processes important prometastatic function \[[@B51]\]. It has been reported that CDK5RAP3 knockdown upregulated the tumor suppressor p14ARF at protein and mRNA levels, and ectopic expression of CDK5RAP3 repressed the transcription of p14ARF \[[@B51]\]. Therefore, the CDK5RAP3 expression may allow for the synthesis of p14ARF and its binding to MDM2. The MDM2 (-0.75) expression was decreased in the D-MG spheroids ([Figure 6](#fig6){ref-type="fig"}). The MDM2 expression can release p53 from inhibition and thereby lead to the stabilization, accumulation, and activation of p53. Also, the negative regulators of p53 are subjected to tight feedback regulation. For example, BCCIP*β* overexpression delays the G1 to S progression and results in an elevated p21 expression, which would inhibit CDK1 induction of cell cycle progression. Though the D-MG spheroids did not show a significant increase in BCCIP*β* expression (0.13) compared to the MG group ([Figure 6](#fig6){ref-type="fig"}), the expression of CDK1 was decreased (-1.72) in the D-MG group, which indicated a potential cell cycle arrest.

### 3.3.4. Wnt Pathway {#sec3.3.4}

In the canonical Wnt pathway, Wnt interacts with the Frizzled receptor that results in the inhibition of glycogen synthase kinase-3*β* (GSK-3*β*) \[[@B52]\]. Due to the inhibition, GSK-3*β* would not be able to phosphorylate *β*-catenin, leading to the nuclear entry of *β*-catenin. In the nucleus, *β*-catenin interacts with members of TCF transcriptional factors (i.e., T cell factor/lymphoid enhancer factor) and modulates target gene expression \[[@B53]\]. In our D-MG spheroids, the expression of *β*-catenin was slightly reduced compared to that in the MG group (CTNNB1, -0.66) ([Figure 7](#fig7){ref-type="fig"}). Wnt 3 (-1.06) and Wnt 5B (-1.55) were also decreased. The histidine triad nucleotide-binding protein 1 (HINT1, 0.23), which keeps the Wnt/*β*-catenin pathway inactive \[[@B54]\], and protein phosphorylase 2A (PPP2RA1, 0.28) were comparable in the two groups. Our previous studies evaluated the influence of the canonical Wnt pathway on neural patterning of hiPSCs \[[@B55], [@B56]\]. The reduced canonical Wnt/*β*-catenin signaling at a late stage of neural differentiation of hiPSCs can enrich cells with rostral forebrain identity \[[@B57]\]. In the noncanonical pathway, Wnt binds to the Frizzled receptor which activates Dishevelled and forms a complex with RAC1, mediating profilin binding to actin \[[@B58]\]. In the current study, the noncanonical Wnt pathway activity was comparable for the D-MG spheroids and MG group (RAC1, 0.27).

### 3.3.5. NF-*κ*B Pathway {#sec3.3.5}

NF-*κ*B was found to be involved in cellular responses to various stimuli such as stress, cytokines, free radicals, and viral antigens \[[@B59], [@B60]\]. The two classes of NF-*κ*B proteins (p50/p52 and ReIA/ReIB) form heterodimers to function as transcriptional activators. In an inactive state, NF-*κ*B dimers are sequestered in the cytoplasm by IkB inhibitors. They mask the nuclear localization signals of NF-*κ*B proteins and keep NF-*κ*B signaling in the inactive state. When active, NF-*κ*B proteins enter the nucleus and turn on the IkB*α* repressor. It has been reported that hypoxia upregulated PRMT1 which asymmetrically methylated ReIA, inhibiting the binding of ReIA to DNA and further repressing NF-*κ*B \[[@B61]\]. NF-*κ*B signaling was found to be dysregulated in TGF*β*R3 epicardial cells, which also showed the impaired cell invasion and revealed the role of NF-*κ*B signaling in TGF*β*R3 activation \[[@B62]\]. In our D-MG spheroids, the lower expression of TGF*β*R3 (-2.61) and TGFB1 (-0.60) indicates the less activated NF-*κ*B pathway (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"} and [Figure 4(b)](#fig4){ref-type="fig"}). TGFBI expression is essentially similar (0.03), and PRMT1 expression (0.63) is slightly upregulated.

Microglial M1 immune response usually involves NF-*κ*B signaling \[[@B59]\]. Knocking down of LRP1 in primary microglia led to the activation of both c-Jun N-terminal kinase and NF-*κ*B pathways. The sensitivity to lipopolysaccharide (LPS) stimulation in the production of proinflammatory cytokines was also enhanced. The NF-*κ*B inhibitor was shown not only to suppress the production of cytokines induced by the knockdown of LRP1 but also to restore the downregulated expression of LRP1 due to LPS stimulation.

### 3.3.6. Notch Pathway {#sec3.3.6}

Most Notch receptors were upregulated in the D-MG group, including DLL1 (5.85), DLL3 (2.84), DLL4 (1.49), JAG1 (2.55), JAG2 (1.70), HES1 (0.62), HES4 (2.44), and HES5 (7.93) ([Figure 8(a)](#fig8){ref-type="fig"}), indicating the enhanced cell-cell communications in 3-D culture. Our previous study also showed that Notch-1 expression was upregulated in the hybrid stem cell spheroids \[[@B63]\]. In addition, Notch signaling regulates the balance between the progenitor pool and the neuron pool, preventing premature neurogenesis \[[@B64]\]. Global deletion of Notch signaling leads to the accelerated differentiation into neurons. The activation of Notch by DLL1 causes neural stem cells to irreversibly commit to a glial fate and prevents the stem cells from adopting a neuronal fate \[[@B65]\]. When a Notch receptor interacts with its ligands, Delta and Serrate, it activates the membrane-tethered transcription factor and leads to the release of intracellular domain (NICD) and its translocation to the nucleus. Then, NICD interacts with CSL family regulators and transcript Hes1 and Hes5 expression. Notch signaling also promotes Wnt expression in Drosophila development \[[@B66]\]. Conversely, Wnt protein can promote the expression of Notch ligands DLLs, forming a positive feedback loop to maintain Notch signaling and Wnt protein expression.

### 3.3.7. Cell Death and Cell Cycle {#sec3.3.7}

It is important to evaluate cell death pathways (necrosis or apoptosis) in the 3-D spheroids. The major changes associated with cell death are free radical damage, swelling, rupture, and cytolysis. Under stress, the cells sense DNA damage by the serine/threonine kinase ATM and p53 \[[@B67]\]. p53 accumulates in the mitochondrial matrix and triggers mitochondrial permeability transition (MPT) pore (PTP) opening. Then, p53 physically interacts with anti- and proapoptotic Bcl-2 and BAX family members to inhibit or activate their respective functions, leading to mitochondrial outer membrane permeabilization (MOMP) and apoptosis \[[@B68]\]. From our results, PPID (0.74), the essential component of the MPT pore located in the mitochondrial matrix, is slightly increased in the D-MG group ([Figure 8(b)](#fig8){ref-type="fig"}).

The exact molecular composition of the MOMP complex is assumed to contain hexokinase, voltage-dependent anion channel (VDAC, on the outer membrane), the adenine nucleotide translocase (ANT, in the inner membrane), and cyclophilin D (a peptidyl-prolyl isomerase in the matrix). When PTP opens, it leads to matrix swelling and depolarization of the membrane potential, causing subsequent rupture of the outer membrane and consequently apoptosis \[[@B68]\]. Based on our results, VDACs were increased (VDAC1, 1.84; VDAC3, 0.90) in the D-MG group ([Figure 8(b)](#fig8){ref-type="fig"}). MPT-driven necrosis works not only by the dissipation of mitochondrial transmembrane potential but also by the latent chromatinolytic activity of AIFM1 (apoptosis-inducing factor mitochondrion-associated 1) \[[@B69]\]. The slightly decreased AIFM1 (-0.38) in the D-MG spheroids indicates that necrosis is favored over apoptosis.

The mitochondrial HINT2 promotes angiogenesis via p53 and BAX. The activated NF-*κ*B pathway also leads to the increased expression of antiapoptotic proteins, including Bcl-XL-binding protein v68 (PGAM5, 1.09) and Bcl-2-associated transcription factor 1 (BCLAF1, 0.96) in the D-MG spheroids ([Figure 8(b)](#fig8){ref-type="fig"}). The defender against apoptotic cell death (DAD1, 0.11) and Bcl-2 inhibitor of transcription 1 (PTRH2, 0.07) were unchanged. These antiapoptotic proteins can bind to and inactivate proapoptotic proteins. The proapoptotic protein BAX, Bcl-2-like protein 4, was unchanged (-0.02), but Bcl-2-associated athanogene 2 (BAG2, -2.90) was decreased in the D-MG spheroids. Consistent with higher expression of death genes in the D-MG group, the cell cycle-related genes were downregulated in the D-MG spheroids but highly expressed in the MG group ([Figure 8(c)](#fig8){ref-type="fig"}).

The sirtuin signaling proteins SIRT1 (0.48) and SIRT6 (1.01) were upregulated in the D-MG spheroids ([Table 3](#tab3){ref-type="table"}), which regulate DNA damage and oxidative stress. The autophagy-related genes were essentially similar between the two groups. Poly (ADP-ribose) polymerase (PARP) is a family of proteins involved in a number of cellular processes such as DNA repair, genomic stability, and programmed cell death \[[@B70]\]. PARP6 (1.32), PARP3 (1.12), and PARP2 (0.97) were upregulated while PARP4 (-1.34), PARP14 (-2.44), PARP12 (-2.54), and PARP9 (-2.76) were downregulated in the D-MG group ([Table 4](#tab4){ref-type="table"}). PARP1 (-0.01) was essentially unchanged between the two groups.

### 3.3.8. Eukaryotic Initiation Factor 2 (eIF2) Pathway {#sec3.3.8}

eIF2 is one of the critical translation G proteins that are tightly regulated in the integrated stress response. In response to stress stimuli, eIF2*α* undergoes phosphorylation via different kinases, such as PKR-like endoplasmic reticulum kinase (PERK), which results in the formation of eIF2B. This blocks the p-eIF2 from its active GTP-bound state, causing a reduction of the translation of most mRNAs \[[@B71]\]. In the operative nervous systems, the eIF pathway was found to support the connectivity between neurons. The physiological extracellular cue Sema3A can trigger rapid and transient phosphorylation of eIF2a in axons for the axonal translational changes \[[@B72]\]. The D-MG group displayed the slightly elevated expression of eIF proteins, such as eIF-2*α*/EIF2S1 (0.220), eIF2*β*/EIF2S2 (0.274), and eIF2B proteins, such as EIF2B1 (0.43), EIF2B2 (0.47), EIF2B3 (0.45), and EIF2B5 (0.66) ([Figure 8(d)](#fig8){ref-type="fig"}), indicating potential stress such as hypoxia or insufficient nutrient uptake in the D-MG group. Also, the expression of EIF2AK3 (0.64), a stress sensing protein kinase that phosphorylates the alpha subunit of eIF2, was slightly elevated in the D-MG group. DDIT3 (0.58), which plays an essential role in inducing cell cycle arrest and apoptosis in response to ER stress, was also slightly elevated in the D-MG group. PPP1R15A (1.17) dephosphorylates the eIF-2*α*/EIF2S1, thereby reversing the shutoff of protein synthesis initiated by stress-inducible kinases and then facilitating cell recovery from stress.

### 3.3.9. Extracellular Matrix {#sec3.3.9}

The extracellular matrix- (ECM-) related genes were found to be differentially expressed in the two groups (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}) \[[@B1]\]. The D-MG group had higher expression of some collagen genes including COL7A1, COL20A1, COL9A1, and COL11A2. The MG group expressed high levels of different types of collagens, including COL23A1, COL6A1, COL4A1, COL13A1, COL5A2, COL5A1, COL14A1, and COL4A1 \[[@B2]\]. The D-MG group mainly enriched laminin LAMB4, while the MG group enriched LAMA3, LAMB1, LAMC1, LAMA2, LAMA1, etc. \[[@B3]\]. The D-MG group expressed higher levels of specific integrins, including ITGA7, ITGB8, ITGA2, and ITGAB3, while the MG group enriched ITGA6, ITGA11, ITGA8, ITGB6, ITGA1, ITGB5, etc. \[[@B4]\]. For ECM remodeling genes, the D-MG group enriched proteases MMP17, MMP10, MMP24, MMP7, and MMP1; the MG group had higher expression of proteases MMP23, MMP2, MMP14, TIMP1, MMP28, MMP26, and MMP15, etc.

Other pathways of our interests are shown in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}, which include the AMPK pathway and PDL1/PD1 pathway ([Figure 9](#fig9){ref-type="fig"} shows the relationship between miRNAs and PDL1/PD1 interactions) ([Figure 9](#fig9){ref-type="fig"}) \[[@B73]\]. Microglia, the main antigen-presenting cells in the human brain, maintain the equilibrium with T cells through the PD1 pathway as reported \[[@B74]\].

4. Conclusions {#sec4}
==============

The genomics data reveal that the D-MG spheroids have higher expression of genes for glycolysis and hypoxia signaling, showing the metabolic shift to aerobic glycolysis, consistent with M1 polarization of microglia. However, glutamine conversion is not activated. The signaling pathway activities (activation of mTOR and p53, repression of NF-*κ*B and canonical Wnt) are consistent with the slower proliferation rate and the accumulation of differentiated cells. The additional NADPH needed for citrate and lipid synthesis is mainly generated by pentose phosphate pathway activation. The reduction in the proliferation rate allows the cells to achieve higher ATP levels in the spheroids. The D-MG group enriches genes for NOTCH signaling, but not canonical Wnt signaling. The MG group has higher expression of genes related to cell cycle and proliferation. These results can help to establish better coculturing methods for efficiently mimicking the *in vivo* structure of the central nervous system.
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Additional Points
=================

*Significance*. Most current forebrain spheroids or organoids lack the components of microglia. This study uses the genomics tool to analyze various pathways of dorsal forebrain spheroids/organoids integrated with isogenic microglia-like cells derived from human induced pluripotent stem cells. The metabolic shift to aerobic glycolysis, consistent with M1 polarization of microglia, in the cocultured spheroids was observed. This study enhances our understanding of 3-D coculturing impacts on the metabolic programming of cells inside the forebrain spheroids. The results can be used to establish better coculturing methods for efficiently mimicking *in vivo* structure of the central nervous system.

Disclosure
==========

Liqing Song\'s current address is College of Medicine, Vanderbilt University, Nashville, Tennessee, USA. Julie Bejoy\'s current address is Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Part of the results of this study will be presented in 2019 Annual Meeting of American Institute of Chemical Engineers (AIChE), Nov 10-15, 2019, Orlando, FL.

Conflicts of Interest
=====================

No competing financial interests exist.

Authors\' Contributions
=======================

JB wrote the first version of the manuscript, did some analysis, and prepared most figures. XY did critical reviews and prepared some figures. LS performed the differentiation procedure and prepared genomics samples. TH and QS helped in microglial differentiation. RJ helped in data analysis and manuscript review. SS reanalyzed the results for figures and validated the statistical analysis. YL conceived the projects and wrote and revised the manuscript.

Supplementary Materials {#supplementary-material-1}
=======================

###### 

Supplementary Table S1: primer sequence for target genes, Supplementary Table S2: genes related to ATP synthesis and mitochondrial complexes I, III, and IV. Supplementary Table S3: genes related to the NF-*κ*B pathway. Supplementary Table S4: AMPK pathway and PDL1/PD1 pathway. Supplementary Figure S1: microglial differentiation using additional human iPSC line: Ep-iPSC. Supplementary Figure S2: regulation of central metabolism in D-MG. Supplementary Figure S3: log2 gene expression levels of D-MG/MG ratios for ECM-related genes.

###### 

Click here for additional data file.

![Illustration of the MG group and D-MG group. (a) Derivation of microglia-like cells (MG) from hiPSCs. (b) Incorporation of MG into the isogenic dorsal spheroids (DMG). (c) Morphology of the cells in microglial differentiation and the D-MG spheroids. Day 30 MGs were labeled with CellTracker Red. White scale bar: 100 *μ*m. Black scale bar: 200 *μ*m.](SCI2019-2382534.001){#fig1}

![Ratios of gene abundance of central metabolic pathways in the D-MG group in comparison to the MG group. The FPKM (fragments per kilobase per million reads) normalized values for these genes are listed for both samples. The numbers are the log2 values of ratios of D-MG to MG. Negative values indicate that the genes are present in higher amounts in the MG group, while positive values indicate that the genes are present in higher amounts in the D-MG group. (a) Central metabolic pathways. (b) Log2 values of glycolysis genes of D-MG/MG ratios.](SCI2019-2382534.002){#fig2}

![HIF-1*α*-related pathway. (a) RNA-sequencing results for glycolytic genes and HIF-1*α*; relative transcript expression between D-MG and MG for HIF-1*α* and its downstream targets (b) on tricarboxylic cycle (TCA) and (c) on glycolysis and extracellular matrix (ECM) production. ∗ indicates *p* \< 0.05 (*n* = 3). (d) Validation of glycolytic genes using RT-PCR. ∗ indicates *p* \< 0.05 (*n* = 3). (e) Schematic diagram showing the major changes in D-MG versus MG for HIF-1*α* signaling: D-MG shows enhanced HIF-1*α* activities that reduce TCA and ATP production, increasing glycolysis mediated by HIF-1*α*.](SCI2019-2382534.003){#fig3}

![mTOR signaling in the D-MG group. (a) RNA-sequencing results. (b) Validation of ERK genes using RT-PCR. ∗ indicates *p* \< 0.05 (*n* = 3). (c) Schematic diagram showing the major changes in D-MG versus MG condition for mTOR signaling. D-MG shows enhanced mTOR activities that reduce tricarboxylic cycle (TCA), and D-MG shows increased glycolysis mediated by mTOR.](SCI2019-2382534.004){#fig4}

![c-Myc signaling in the D-MG group. (a) RNA-sequencing results related to Myc. (b) Relative transcript expression between D-MG and MG conditions for c-Myc and its downstream targets; ∗ indicates *p* \< 0.05 (*N* = 3). (c) Schematic diagram showing the major changes in D-MG versus MG for c-Myc signaling: D-MG shows enhanced c-Myc that mediates increased glycolysis.](SCI2019-2382534.005){#fig5}

![p53 signaling in the D-MG group. (a) RNA-sequencing results related to p53. (b) Relative transcript expression between D-MG and MG for p53 and its downstream targets; ∗ indicates *p* \< 0.05 (*N* = 3). (c) Schematic diagram showing the major changes in D-MG versus MG for p53 signaling: D-MG shows the increased p53 activities, which results in the decreased expression of proteins related to cell proliferation.](SCI2019-2382534.006){#fig6}

![Wnt signaling in the D-MG group. (a) RNA-sequencing results related to Wnt. (b) Relative transcript expression between D-MG and MG for Wnt and its downstream targets. ∗ indicates *p* \< 0.05 (*N* = 3). (c) Schematic diagram showing the major changes in D-MG versus MG conditions for Wnt signaling; i.e., D-MG shows the decreased canonical Wnt signaling while noncanonical Wnt is increased, which results in the increased cytoskeletal rearrangement.](SCI2019-2382534.007){#fig7}

![Log2 expression levels of the D-MG/MG ratios for genes about cell-cell interactions, cell death, and cell cycle. (a) Notch signaling. (b) Cell death. (c) Cell cycle and cell proliferation. (d) EIF2 signaling as a part of integrated stress response (ISR).](SCI2019-2382534.008){#fig8}

![Illustration of microglia with PDL1/PD1 interactions. The numbers in the illustration are from the normal DMG/MG ratios. The arrows show the ways of tumor cell and T cell interactions. MGs act as antigen-presenting cells (APC).](SCI2019-2382534.009){#fig9}

###### 

Glycolysis vs. oxidative phosphorylation.

  Gene name        MG-1       MG-2       MG-3       D-MG-1    D-MG-2    D-MG-3    MG ave    DMG ave    DMG/MG   LOG2 (DMG/MG)
  ---------------- ---------- ---------- ---------- --------- --------- --------- --------- ---------- -------- ---------------
  P4HA1            140.340    135.633    141.039    389.230   546.723   505.399   139.004   480.451    3.456    1.79
  SLC2A1 (GLUT1)   579.1676   469.9516   562.8377   912.218   1098.52   1056.15   537.319   1022.293   1.903    0.93
  DLST             17.881     18.114     17.362     26.470    26.133    24.754    17.786    25.786     1.450    0.54
  SLC16A3          304.016    219.663    293.687    255.760   244.563   255.972   272.455   252.098    0.925    -0.11
  COX4I1           238.629    185.922    239.199    186.813   225.728   199.922   221.250   204.154    0.923    -0.12
  SLC25A1          72.139     59.151     72.118     54.289    60.972    56.058    67.803    57.107     0.842    -0.25
  DLD              22.476     21.521     21.854     12.507    12.003    14.700    21.950    13.070     0.595    -0.75
  OGDH             28.692     23.353     27.126     8.233     7.421     8.492     26.390    8.049      0.305    -1.71

The FPKM (fragments per kilobase per million reads) normalized values for these genes are listed for both samples. The numbers are the log2 values of ratios of D-MG to MG. Negative values indicate that the genes are present in higher amounts in the MG group, while positive values indicate that the genes are present in higher amounts in the D-MG group. The value 1 indicates two-fold change.

###### 

Rate-limiting enzymes for central metabolic pathways and the ratios of their expression in the D-MG group compared to the MG group.

  Pathway                          Gene name   MG-1      MG-2      MG-3      D-MG-1     D-MG-2     D-MG-3     MG ave    DMG ave    LOG2 (DMG/MG)
  -------------------------------- ----------- --------- --------- --------- ---------- ---------- ---------- --------- ---------- ---------------
  Glucose phosphorylation          HK2         8.057     7.382     8.514     373.333    367.184    391.036    7.984     377.184    5.56
  Glycolysis                       PKM         144.193   130.476   142.160   1071.419   1269.244   1061.022   138.943   1133.895   3.03
  Glycine synthesis                SHMT2       34.121    29.636    33.060    146.550    175.435    141.673    32.272    154.553    2.26
  Asparagine synthesis             ASNS        28.779    28.424    28.878    93.603     122.579    101.086    28.694    105.756    1.88
  Glycogenolysis                   PYGB        25.047    22.544    24.888    34.525     34.766     30.397     24.159    33.229     0.46
  Pyrimidine synthesis             CAD         8.199     9.554     8.489     13.220     12.638     10.185     8.747     12.015     0.46
  Glycolysis                       PFKL        62.436    52.127    63.963    83.298     79.339     73.566     59.509    78.734     0.40
  Aspartate synthesis              GOT1        16.089    14.826    14.507    18.869     20.440     19.010     15.141    19.439     0.36
  Fatty acid synthesis             FASN        28.814    22.644    29.725    36.264     34.796     31.673     27.061    34.244     0.34
  Purine synthesis                 PRPS1       23.085    20.259    22.740    24.847     28.698     27.976     22.028    27.173     0.30
  Pentose phosphate                G6PD        15.355    12.245    15.422    12.237     14.129     12.097     14.341    12.821     -0.16
  Fatty acid synthesis             ACAA1       21.219    19.891    21.847    17.973     18.352     15.681     20.986    17.336     -0.28
  Glutamine-glutamate conversion   GLUD1       49.375    44.127    51.590    35.530     41.837     38.198     48.364    38.522     -0.33
  Methionine synthesis             MTR         7.799     9.359     8.511     7.162      5.777      6.920      8.556     6.620      -0.37
  TCA cycle                        IDH2        103.753   84.981    101.212   66.326     79.889     75.170     96.649    73.795     -0.39
  Serine synthesis                 PHGDH       141.285   116.771   138.838   92.636     114.237    92.781     132.298   99.884     -0.41
  Hexose                           GFPT1       46.208    45.599    46.304    26.099     32.086     29.340     46.037    29.175     -0.66
  Fatty acid oxidation             CRAT        23.955    20.886    25.945    14.810     14.697     14.392     23.596    14.633     -0.69
  Proline synthesis                PYCR1       102.329   84.127    98.191    46.173     65.047     53.249     94.883    54.823     -0.79
  Urea synthesis                   CPS1        7.949     7.541     8.583     4.041      3.943      4.177      8.024     4.054      -0.99
  Tyrosine synthesis               PAH         0.441     0.551     0.468     0.171      0.184      0.224      0.487     0.193      -1.33
  Cysteine synthesis               MAT1A       5.443     4.897     5.280     0.793      0.724      0.529      5.207     0.682      -2.93

The FPKM (fragments per kilobase per million reads) normalized values for these genes are listed for both samples. The numbers are the log2 values of ratios of D-MG to MG. Negative values indicate that the genes are present in higher amounts in the MG group, while positive values indicate that the genes are present in higher amounts in the D-MG group. The value 1 indicates two-fold change.

###### 

Sirtuin signaling and autophagy.

  Gene name             MG-1     MG-2     MG-3     D-MG-1   D-MG-2   D-MG-3   MG ave   DMG ave   DMG/MG   LOG2 (D-MG/MG)
  --------------------- -------- -------- -------- -------- -------- -------- -------- --------- -------- ----------------
  *Sirtuin signaling*                                                                                     
  SIRT6                 11.268   9.088    9.289    20.250   21.520   17.741   9.882    19.837    2.007    1.01
  SIRT1                 8.625    8.714    9.529    12.048   12.060   13.258   8.956    12.455    1.391    0.48
  SIRT4                 3.945    5.113    3.877    5.457    4.254    5.735    4.312    5.148     1.194    0.26
  SIRT7                 7.837    8.696    7.100    8.127    7.686    7.362    7.877    7.725     0.981    -0.03
  SIRT5                 1.763    2.161    1.591    1.743    1.551    1.505    1.838    1.599     0.870    -0.20
  SIRT3                 13.160   13.397   12.523   8.864    7.755    8.300    13.027   8.306     0.638    -0.65
  SIRT2                 50.715   42.689   48.365   27.236   31.360   27.618   47.256   28.738    0.608    -0.72
  *Autophagy*                                                                                             
  TFEB                  5.357    4.069    5.025    4.723    5.425    5.416    4.817    5.188     1.077    0.11
  BECN1                 13.675   11.764   13.135   12.298   12.239   12.236   12.858   12.257    0.953    -0.07
  LAMP1                 57.074   48.954   58.426   46.114   51.499   47.309   54.818   48.307    0.881    -0.72

The FPKM (fragments per kilobase per million reads) normalized values for these genes are listed for both samples. The numbers are the log2 values of ratios of D-MG to MG. Negative values indicate that the genes are present in higher amounts in the MG group, while positive values indicate that the genes are present in higher amounts in the D-MG group. The value 1 indicates two-fold change.

###### 

Gene expression of poly (ADP-ribose) polymerase (PARP) family proteins.

  Gene name   MG-1     MG-2     MG-3     D-MG-1   D-MG-2   D-MG-3   MG ave   DMG ave   DMG/MG   LOG2 (D-MG/MG)
  ----------- -------- -------- -------- -------- -------- -------- -------- --------- -------- ----------------
  PARP6       19.908   24.159   20.683   55.689   59.154   54.018   21.583   56.287    2.608    1.38
  PARP3       3.171    3.020    3.221    6.723    7.323    6.366    3.137    6.804     2.169    1.12
  PARP2       17.659   22.634   16.142   35.570   39.811   34.828   18.812   36.736    1.953    0.97
  PARP11      3.485    3.789    3.403    6.320    6.097    6.702    3.559    6.373     1.791    0.84
  PARP15      0.163    0.124    0.127    0.286    0.263    0.179    0.138    0.243     1.759    0.81
  PARP8       2.142    2.526    2.428    3.305    3.204    3.578    2.365    3.362     1.422    0.51
  PARP1       42.914   40.611   42.447   41.423   43.048   40.686   41.990   41.719    0.994    -0.01
  PARP10      1.451    1.234    1.709    1.518    1.198    1.385    1.465    1.367     0.933    -0.10
  PARP16      12.871   12.281   11.812   7.840    8.730    9.558    12.321   8.709     0.707    -0.50
  PARP4       8.746    9.413    8.348    3.874    3.104    3.526    8.836    3.501     0.396    -1.34
  PARP14      7.616    10.770   8.298    1.482    1.613    1.818    8.895    1.638     0.184    -2.44
  PARP12      1.519    1.168    1.288    0.182    0.274    0.228    1.325    0.228     0.172    -2.54
  PARP9       3.633    3.688    3.397    0.533    0.460    0.586    3.573    0.526     0.147    -2.76

The FPKM (fragments per kilobase per million reads) normalized values for these genes are listed for both samples. The numbers are the log2 values of ratios of D-MG to MG. Negative values indicate that the genes are present in higher amounts in the MG group, while positive values indicate that the genes are present in higher amounts in the D-MG group. The value 1 indicates two-fold change.

[^1]: Guest Editor: Monica Montesi
